ADVFN US – Market Content Editor
-
Anavex Receives FDA IND Clearance for Blarcamesine in Fragile X Syndrome, Enabling Phase 2a Trial
Anavex Life Sciences gains regulatory clearance to begin U.S. clinical testing of blarcamesine for Fragile X syndrome, expanding its active development programs across three neurological indications. Key Investor Takeaways Why AVXL Stock Is in Focus Anavex Life Sciences (NASDAQ:AVXL) has secured FDA IND clearance for its investigational drug ANAVEX2-73, also known as blarcamesine, in Fragile…
-
Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans
Fractyl Health reports statistically significant reductions in weight regain following GLP-1 discontinuation, advancing its Revita treatment toward a potential FDA submission in late 2026. Key Investor Takeaways Why GUTS Stock Is in Focus Fractyl Health (NASDAQ:GUTS) has reported positive six-month results from its ongoing REMAIN-1 pivotal trial, meeting the first of two co-primary endpoints for…
-
SANGRIX Sets November 2026 Delivery Schedule for 128 NVIDIA Blackwell B300 GPUs in Malaysia
SANGRIX advances its AI infrastructure deployment plans with a revised delivery timetable for its $11 million server project, shifting attention toward commissioning and commercial operations. Key Investor Takeaways Why SGRX Stock Is in Focus SANGRIX (NASDAQ:SGRX), formerly Bit Origin Ltd, has established a November 2026 delivery schedule for its first NVIDIA Blackwell B300 AI infrastructure…
-
US Import and Export Prices Rise More Than Expected in September
US import and export prices increased significantly more than economists had anticipated in September, according to figures released by the US Department of Labor on Friday, indicating continued price pressures in international trade. Import prices rose 1.1% during the month, accelerating from a downwardly revised 0.5% increase in August. Economists had forecast a 0.6% rise,…
-
US Stocks Set for Muted Open as Investors Assess Inflation Data and Technology Sector Volatility: Dow Jones, S&P, Nasdaq, Wall Street
US stock futures pointed to a broadly unchanged opening on Friday as investors assessed recent market volatility, stronger-than-expected inflation figures and the outlook for technology shares. Wall Street recovered sharply during Thursday’s session after initially extending Wednesday’s technology-led sell-off. The Nasdaq rebounded from its lowest intraday level in almost a month, while the Dow Jones…
-
Travelers Shares Fall 4.4% Despite Third-Quarter Earnings and Revenue Beating Estimates
The Travelers Companies, Inc. (NYSE:TRV) reported third-quarter 2026 earnings and revenue above Wall Street expectations on Friday, although its shares declined approximately 4.4% in premarket trading as catastrophe losses increased compared with the previous year. The US insurer posted adjusted earnings per share of $9.18, exceeding the analyst consensus estimate of $7.25. Revenue reached $12.41…
-
NiSource Signs 20-Year Microsoft Power Agreement for 1,100 MW Indiana Data Centre Campus
NiSource Inc. (NYSE:NI) has entered into a 20-year energy agreement with Microsoft Corporation (NASDAQ:MSFT) to supply approximately 1,100 megawatts (MW) of generation resources to a data centre campus in northwest Indiana. Electricity service is expected to begin in 2028, with Microsoft agreeing to fund the generation and transmission infrastructure required to meet the facility’s power…
-
WeShop Secures Up to $25 Million Equity Financing Facility With Roth Principal Investments
WeShop Holdings Limited (NASDAQ:WSHP) has announced a committed equity financing facility of up to $25 million with Roth Principal Investments, LLC, providing the company with access to additional capital as it pursues expansion in the United States. The agreement, signed on 9 September 2026, allows WeShop to issue and sell Class A ordinary shares to…
-
Omeros Shares Fall 4% as European Regulators Uphold Negative Opinion on Narsoplimab
Omeros Corporation (NASDAQ:OMER) shares declined 4% in Friday morning trading after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) maintained its negative opinion on the company’s marketing authorisation application for narsoplimab. The decision followed a formal re-examination of the application for narsoplimab as a treatment for haematopoietic stem cell transplant-associated…
-
Zenta Group’s ZentoAI Signs MOU for Proposed Acquisition of Chinese AI and Big Data Technology Company
Zenta Group Company Limited (NASDAQ:ZTG), a Macau-based professional services provider, has announced that its subsidiary, ZentoAI Intelligent Technology Company Limited, has signed a memorandum of understanding (MOU) concerning the proposed acquisition of a controlling interest in a privately held digital technology company in mainland China. The potential acquisition forms part of Zenta Group’s strategy to…